[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX368228B - Anticuerpos que se unen específicamente a her2. - Google Patents

Anticuerpos que se unen específicamente a her2.

Info

Publication number
MX368228B
MX368228B MX2015015110A MX2015015110A MX368228B MX 368228 B MX368228 B MX 368228B MX 2015015110 A MX2015015110 A MX 2015015110A MX 2015015110 A MX2015015110 A MX 2015015110A MX 368228 B MX368228 B MX 368228B
Authority
MX
Mexico
Prior art keywords
antibody
her2
present
cancer
trastuzumab
Prior art date
Application number
MX2015015110A
Other languages
English (en)
Other versions
MX2015015110A (es
Inventor
Lee Jong-Seo
Kim Kyu-Tae
Lee Young-Ha
LEE Sook-Yeon
Hwang In-Sik
KO Bong-Kook
Original Assignee
Abclon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abclon Inc filed Critical Abclon Inc
Publication of MX2015015110A publication Critical patent/MX2015015110A/es
Publication of MX368228B publication Critical patent/MX368228B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo HER2 novedoso para su administración simultánea, que se utiliza para prevenir o tratar cáncer. El anticuerpo de la presente invención se une específicamente a HER2, el cual se sobre-expresa en células de cáncer (particularmente, en células de cáncer de mama y cáncer gástrico), y se une a un epítopo diferente de aquel al cual se une trastuzumab. El anticuerpo de la presente invención tiene una secuencia única debido a una homología muy baja comparada con la secuencia CDR de los anticuerpos dirigidos a HER2 conocidos. El anticuerpo de la presente invención extermina células de cáncer con una capacidad notablemente mejorada para exterminar células de cáncer cuando se administra simultáneamente con trastuzumab y de este modo, es muy útil para prevenir o tratar cáncer (particularmente cáncer de mama o cáncer gástrico). La eficacia notable de la administración simultánea del anticuerpo de la presente invención se considera, sin desear limitarse por la teoría que se debe a que el anticuerpo de la presente invención se une a un epítopo de HER2 diferente al que se une trastuzumab, inhibiendo por lo tanto HER2 de forma cooperativa con trastuzumab.
MX2015015110A 2013-05-16 2014-05-14 Anticuerpos que se unen específicamente a her2. MX368228B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130055912 2013-05-16
PCT/KR2014/004317 WO2014185704A1 (ko) 2013-05-16 2014-05-14 Her2에 특이적으로 결합하는 항체

Publications (2)

Publication Number Publication Date
MX2015015110A MX2015015110A (es) 2016-08-11
MX368228B true MX368228B (es) 2019-09-24

Family

ID=51898619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015110A MX368228B (es) 2013-05-16 2014-05-14 Anticuerpos que se unen específicamente a her2.

Country Status (13)

Country Link
US (1) US10174116B2 (es)
EP (1) EP2998319B1 (es)
JP (2) JP6234548B2 (es)
KR (1) KR101453462B1 (es)
CN (1) CN105164160B (es)
AU (1) AU2014266118B2 (es)
BR (1) BR112015027400B1 (es)
CA (1) CA2910407C (es)
ES (1) ES2710707T3 (es)
HK (1) HK1217500A1 (es)
MX (1) MX368228B (es)
RU (1) RU2628094C2 (es)
WO (1) WO2014185704A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101884585B1 (ko) * 2010-02-10 2018-08-01 우베 고산 가부시키가이샤 폴리이미드 필름, 이를 포함하는 폴리이미드 적층체, 및 이를 포함하는 폴리이미드/금속 적층체
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
KR101796277B1 (ko) * 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 her2에 특이적으로 결합하는 항체
EP3241847A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
CN109476744B (zh) * 2016-05-12 2023-04-11 新加坡科技研究局 抗erbb-2抗体及其用途
US11390685B2 (en) 2017-01-06 2022-07-19 Biosion, Inc. ErbB2 antibodies and uses therefore
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7386796B2 (ja) * 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗-her2抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
CN110790840A (zh) * 2018-08-01 2020-02-14 三生国健药业(上海)股份有限公司 结合人her2的抗体、其制备方法和用途
KR20200098831A (ko) 2019-02-13 2020-08-21 건국대학교 글로컬산학협력단 신규한 부위-특이적 항체 절편 플랫폼
EP3962525A1 (en) * 2019-05-02 2022-03-09 MAB Discovery GmbH Combination of her2 antibodies
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
DE3884529T2 (de) 1987-03-20 1994-04-28 Creative Biomolecules Inc Leader-anteile zur produktion von rekombinanten proteinen.
ATE113985T1 (de) 1987-03-20 1994-11-15 Creative Biomolecules Inc Verfahren zur reinigung von rekombinanten polypeptiden.
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
CN101412758A (zh) * 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
CN103127502A (zh) 2004-05-20 2013-06-05 津莫吉尼蒂克斯公司 使用il-21和单克隆抗体疗法治疗癌症的方法
KR20070038557A (ko) * 2004-07-22 2007-04-10 제넨테크, 인크. Her2 항체 조성물
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1結合タンパク質
JP5638804B2 (ja) * 2006-08-04 2014-12-10 アストラゼネカ アクチボラグ ErbB2に対する抗体
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
US9155753B2 (en) 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
WO2011001276A1 (en) 2009-06-30 2011-01-06 Philogen S.P.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2

Also Published As

Publication number Publication date
EP2998319A4 (en) 2017-01-25
CA2910407A1 (en) 2014-11-20
BR112015027400A2 (pt) 2017-08-29
CN105164160B (zh) 2018-11-30
RU2628094C2 (ru) 2017-08-14
CN105164160A (zh) 2015-12-16
US10174116B2 (en) 2019-01-08
WO2014185704A1 (ko) 2014-11-20
EP2998319B1 (en) 2018-11-28
RU2015146664A (ru) 2017-06-21
AU2014266118B2 (en) 2017-03-30
ES2710707T3 (es) 2019-04-26
JP6234548B2 (ja) 2017-11-22
AU2014266118A1 (en) 2015-11-12
BR112015027400B1 (pt) 2023-04-25
JP2016518368A (ja) 2016-06-23
KR101453462B1 (ko) 2014-10-23
US20160053011A1 (en) 2016-02-25
JP6487968B2 (ja) 2019-03-20
EP2998319A1 (en) 2016-03-23
HK1217500A1 (zh) 2017-01-13
MX2015015110A (es) 2016-08-11
CA2910407C (en) 2018-12-11
JP2018008954A (ja) 2018-01-18

Similar Documents

Publication Publication Date Title
MX2015015110A (es) Anticuerpos que se unen especificamente a her2.
SA522431756B1 (ar) Tigit أجسام مضادة لـ
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2014001374A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
PH12016501672A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2017016253A (es) Anticuerpos para cd40.
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
TN2015000396A1 (en) Antibody drug conjugates
MX2016005666A (es) Anticuerpos anti-cd38 especificos para tratar canceres humanos.
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
NZ630864A (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
MX2018014560A (es) Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
MX2020002406A (es) Anticuerpo anti-epha4.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
NZ625758A (en) Method for treating breast cancer
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.

Legal Events

Date Code Title Description
FG Grant or registration